Close the acquisition of Eidos Therapeutics
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Jan 2021
- Due
- 26 Jan 2021
- Delivered
- 26 Jan 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing.”
What we found
Evidence strength A What the grades mean
BridgeBio Pharma completed its acquisition of Eidos Therapeutics on January 26, 2021, as announced in its SEC filings.
-
A BridgeBio Pharma, Inc. 8-K filed 2021-01-26
“BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc.” ✓ confirmed on the page
-
A BridgeBio Pharma, Inc. 10-Q filed 2021-05-06
“on January 26, 2021, we closed and completed the Merger Transactions.” ✓ confirmed on the page
Market reaction: the shares moved -12.7% against the S&P 500 over the three sessions around the disclosure (25 Jan 2021 to 28 Jan 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Eidos Therapeutics
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to the satisfaction or waiver of other conditions to closing
- Depends on
- Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you BridgeBio Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BBIO-022240 · Corrections policy